About
Igenomix is a pioneer in reproductive genetics with more than 15 years of experience and a presence across 20 laboratories worldwide. Founded in 2011 and acquired by Vitrolife in 2021, Igenomix operates as part of Vitrolife Group — a global leader in reproductive health. The platform provides a comprehensive suite of genetic testing services designed for fertility specialists and their patients, spanning three key stages of reproduction: preconception, preimplantation, and prenatal. Key offerings include the ERA (Endometrial Receptivity Analysis) test for identifying the optimal window of embryo implantation, EndomeTRIO for a complete view of endometrial health, PGT-A (Preimplantation Genetic Testing for Aneuploidies) to improve IVF success rates, PGT-M for inherited genetic disorder screening, and PGT-SR for structural chromosomal rearrangements. Additional tests such as EMMA (Endometrial Microbiome Metagenomic Analysis), ALICE, and CGT (Carrier Genetic Test) round out their preconception portfolio. Igenomix serves reproductive health specialists at fertility clinics globally, offering educational resources, webinars, a dedicated clinic portal, and genetic counseling. With over 600 professionals, 4 patents, and 500+ scientific publications, Igenomix is a trusted partner for evidence-based reproductive care. It is ideal for IVF clinics, fertility specialists, and patients experiencing recurrent implantation failure or seeking preconception genetic insights.
Key Features
- ERA (Endometrial Receptivity Analysis): Identifies the precise window of implantation in a patient's uterus to optimize the timing of embryo transfer and improve IVF success rates.
- EndomeTRIO: A comprehensive endometrial health panel combining ERA, EMMA, and ALICE tests to evaluate receptivity, microbiome composition, and infection markers in a single analysis.
- PGT-A & PGT-M Testing: Preimplantation genetic testing for aneuploidies and monogenic diseases helps screen embryos before transfer, reducing the risk of miscarriage and inherited genetic disorders.
- Global Lab Network: Operates 20 laboratories worldwide with CAP accreditation, ensuring high-quality, standardized genetic analysis for clinics across multiple continents.
- Genetic Counseling & Education: Offers patient and specialist support through genetic counseling requests, educational webinars, videos, and an online academy for reproductive health professionals.
Use Cases
- Fertility clinics use ERA testing to personalize embryo transfer timing for patients with recurrent implantation failure, improving IVF success rates.
- Couples with known hereditary genetic disorders use PGT-M to screen embryos before transfer, significantly reducing the risk of passing on the condition to their child.
- Reproductive endocrinologists order EndomeTRIO to evaluate uterine health holistically — assessing receptivity, microbiome balance, and infection — before initiating IVF treatment.
- IVF programs integrate PGT-A into their protocols to select chromosomally normal embryos, reducing miscarriage rates and improving live birth outcomes.
- Genetic counselors and specialists use Igenomix's carrier genetic testing (CGT) to identify recessive genetic variants in prospective parents before conception, informing family planning decisions.
Pros
- Extensive Scientific Validation: Backed by 500+ peer-reviewed publications and 4 patents, Igenomix tests are among the most scientifically validated tools in reproductive genetics.
- Comprehensive Test Portfolio: Covers the entire reproductive journey — preconception, preimplantation, and prenatal — giving clinics a one-stop solution for genetic diagnostics.
- Global Reach with Local Support: Operates in 20+ countries with dedicated regional portals, multilingual support, and local laboratory infrastructure for fast turnaround.
Cons
- Primarily B2B Focused: Services are largely accessed through fertility clinics and specialists, making it difficult for patients to engage directly without a medical referral.
- Pricing Not Publicly Listed: Test pricing is not transparently available on the website, requiring direct contact or clinic consultation to obtain cost information.
- Specialized Use Case: Igenomix is highly specialized in reproductive genetics and is not applicable to general health diagnostics or broader genomics use cases.
Frequently Asked Questions
What is the ERA test and who is it for?
The ERA (Endometrial Receptivity Analysis) test determines the personalized window of implantation in a patient's uterus. It is recommended for patients who have experienced recurrent implantation failure (RIF) during IVF treatment.
What is the difference between PGT-A and PGT-M?
PGT-A screens embryos for chromosomal abnormalities (aneuploidies) to select the most viable embryos for transfer, while PGT-M is a custom-designed test targeting specific inherited single-gene disorders (monogenic diseases) in families with a known genetic condition.
How does EndomeTRIO work?
EndomeTRIO combines three tests — ERA (receptivity), EMMA (endometrial microbiome), and ALICE (chronic endometritis) — from a single endometrial biopsy sample, providing a complete picture of uterine health in one analysis.
Is Igenomix available for patients directly, or only through clinics?
Igenomix primarily works through fertility clinics and reproductive health specialists. Patients typically access Igenomix tests via a referral from their fertility doctor, though genetic counseling requests can be initiated through the website.
What accreditations does Igenomix hold?
Igenomix's Los Angeles laboratory holds CAP (College of American Pathologists) accreditation. The company maintains rigorous quality standards across its global laboratory network of 20 facilities.
